Drug intelligence / Profile preview

OpCombo

Development stage: Preclinical
Lead developer: Pharma in Silica
Modality: Nanoparticles → Drug Delivery Systems

Overview

OpCombo is a preclinical-stage drug delivery platform developed by Pharma in Silica, utilizing 40nm silica nanoparticles. The platform is designed for the synchronized and controlled release of multiple therapeutic compounds, specifically targeting cancer and hepatic indications. By enabling the timed co-delivery of different active ingredients, OpCombo aims to optimize the synergistic effects of combination therapies while improving the pharmacokinetic profile and reducing the systemic toxicity of the encapsulated agents. This technology is part of the company's broader "Op" series of silica-based nanoparticle delivery systems, which are engineered to provide precise, coordinated release of therapeutic payloads at the target site.

Brand names: OpCombo

Beyond the preview

Go deeper on OpCombo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OpCombo.

Explore the full profile